期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

马尔可夫模型评价三种磷结合剂治疗高磷血症的研究 被引量：3

Markov Model-based Cost-effectiveness Analysis of 3 Phosphate Binder
暂未订购
导出
摘要 目的:评价碳酸钙、碳酸镧和盐酸司维拉姆三者在治疗高磷血症的经济性。方法:通过构建马尔可夫模型进行成本效果评价。结果:碳酸镧降磷效果最好,盐酸司维拉姆次之,碳酸钙最差,但考虑成本之后碳酸钙为最优方案。结论:在3倍人均GDP为支付阈值的条件下碳酸钙是最具有成本效果优势的方案。 Objective： To assess the cost-effectiveness of 3 kinds of phosphate binders as a treatment for hyperphosphatemia. Methods： A Markov model was developed to estimate outcome of QALYs, LYs and cost. Results： Compare to the calcium carbonate, sevelamer hydrochloride was dominated, the ICER of the lanthanum carbonate is ￥160997, higher than the 3 times of GDP/QALY willingness to pay threshold. Concluslon：Calcium carbonate is the most cost-effectiveness strategy.
作者 王世家 陈永法
机构地区 中国药科大学国际医药商学院
出处 《中国药物评价》 2015年第3期162-166,共5页 Chinese Journal of Drug Evaluation
关键词 高磷血症 碳酸镧 盐酸司维拉姆 碳酸钙 Hyperphosphatemia Lanthanum carbonate Sevelamer hydrochloride Calcium carbonate
分类号 R692.5 [医药卫生—泌尿科学]
  • 相关文献

参考文献8

  • 1闵亚丽,杨静,蓝天座,于黔.碳酸镧治疗维持性血液透析患者高磷血症疗效观察[J].中国药业,2014,23(1):89-90. 被引量：13
  • 2赵袆,王敬东,赵东明,董雅梦,高岩.碳酸司维拉姆治疗终末期肾脏病患者高磷血症疗效的随机对照研究[J].中国循证医学杂志,2014,14(11):1293-1298. 被引量：12
  • 3Kakuta T,Tanaka R,Hyodo T,et al. Effect of Sevelamer and Calcium Raseati Based Phosphate Binders on Coronary Artery Calcification and Accumulation of Circulating Advanced Glyeation End Products in Hemodialysis Patients [ J ]. Am J Kidney Dis,2011,57(3) :422-431.
  • 4Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis [J]. Journal of the American So- ciety of Nephrology, 2004, 15(8) :2208-2218.
  • 5Tentori F, Blayney MJ, Albert JM, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS) [ J ]. American Journal of Kidney Diseases, 2008, 52(3) :519-530.
  • 6Joy MS, Finn WF, LAM -302 Study Group. Randomized, double-blind, placebo-controlled, dose-titration, phase nl study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia [J]. American Journal of Kidney Diseases, 2003, 42 ( 1 ) :96-107.
  • 7Ferreira A, Fraso J M, Monier-Faugere M, et al. Effects of Sevelamer Hydrochloride and Calcium Carbonate on Renal Osteodystrophy in Hemodialy- sis Patients [J]. Journal of the American Society of Nephrology, 2008, 19 (2) :405-412.
  • 8Brennan A1, Akehttrst R, Davis S, et al. The Cost-Effectiveness Of Lantha- num Carbonate In The Treatment Of Hyperphosphatemia In Patients With End-Stage Renal Disease[Jl. Value Health, 2007,10(1) :32-41.

二级参考文献39

  • 1Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int, 2007, 71(1): 31-38.
  • 2Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol, 2004, 15(8): 2208-2218.
  • 3Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int, 2006, 70(4): 771-780.
  • 4Slatopolsky E, Brown A, Dusso A. Role of phosphorus in the pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis, 2001, 37(1 Suppl 2): S54-57.
  • 5Prie D, Urena TP, Friedlander G. Latest findings in phosphate homeostasis. Kidney Int, 2009, 75(9): 882-889.
  • 6Block GA, Hulbert-Shearon TE, Levin NW, et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis, 1998, 31(4): 607-617.
  • 7Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis, 1990, 15(5): 458-482.
  • 8Delmez JA, Slatopolsky E. Hyperphosphatemia: its consequences and treatment in patients with chronic renal disease. Am J Kidney Dis,1992, 19(4): 303-317.
  • 9Navaneethan SD, Palmer SC, Craig JC, et al. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Am J Kidney Dis, 2009, 54(4): 619-637.
  • 10Chen N, Wu X, Ding X, et al. Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study. Nephrol Dial Transplant, 2014, 29(1): 152-160.

共引文献22

同被引文献36

引证文献3

二级引证文献17

中国药物评价
2015年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部